Precisely Regulating M2 Subtype Macrophages for Renal Fibrosis Resolution
Macrophages are central to the pathogenesis of kidney disease and serve as an effective therapeutic target for kidney injury and fibrosis. Among them, M2-type macrophages have double-edged effects regarding anti-inflammatory effects and tissue repair. Depending on the polarization of the M2 subtypes (M2a or M2c) in the diseased microenvironment, they can either mediate normal tissue repair or drive tissue fibrosis. In renal fibrosis, M2a promotes disease progression through macrophage-to-myofibroblast transition (MMT) cells, while M2c possesses potent anti-inflammatory functions and promotes tissue repair, and is inhibited. The mechanisms underlying this differentiation are complex and are currently not well understood. Therefore, in this study, we first confirmed that M2a-derived MMT cells are responsible for the development of renal fibrosis and demonstrated that the intensity of TGF-β signaling is a major factor determining the differential polarization of M2a and M2c. Under excessive TGF-β stimulation, M2a undergoes a process known as MMT cells, whereas moderate TGF-β stimulation favors the polarization of M2c phenotype macrophages. Based on these findings, we employed targeted nanotechnology to codeliver endoplasmic reticulum stress (ERS) inhibitor (Ceapin 7, Cea or C) and conventional glucocorticoids (Dexamethasone, Dex or D), precisely modulating the ATF6/TGF-β/Smad3 signaling axis within macrophages. This approach calibrated the level of TGF-β stimulation on macrophages, promoting their polarization toward the M2c phenotype and suppressing excessive MMT polarization. The study indicates that the combination of ERS inhibitor and a first-line anti-inflammatory drug holds promise as an effective therapeutic approach for renal fibrosis resolution.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
ACS nano - 17(2023), 22 vom: 28. Nov., Seite 22508-22526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luo, Lihua [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 05.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsnano.3c05998 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364397608 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364397608 | ||
| 003 | DE-627 | ||
| 005 | 20231226095340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsnano.3c05998 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364397608 | ||
| 035 | |a (NLM)37948096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luo, Lihua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Precisely Regulating M2 Subtype Macrophages for Renal Fibrosis Resolution |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 05.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Macrophages are central to the pathogenesis of kidney disease and serve as an effective therapeutic target for kidney injury and fibrosis. Among them, M2-type macrophages have double-edged effects regarding anti-inflammatory effects and tissue repair. Depending on the polarization of the M2 subtypes (M2a or M2c) in the diseased microenvironment, they can either mediate normal tissue repair or drive tissue fibrosis. In renal fibrosis, M2a promotes disease progression through macrophage-to-myofibroblast transition (MMT) cells, while M2c possesses potent anti-inflammatory functions and promotes tissue repair, and is inhibited. The mechanisms underlying this differentiation are complex and are currently not well understood. Therefore, in this study, we first confirmed that M2a-derived MMT cells are responsible for the development of renal fibrosis and demonstrated that the intensity of TGF-β signaling is a major factor determining the differential polarization of M2a and M2c. Under excessive TGF-β stimulation, M2a undergoes a process known as MMT cells, whereas moderate TGF-β stimulation favors the polarization of M2c phenotype macrophages. Based on these findings, we employed targeted nanotechnology to codeliver endoplasmic reticulum stress (ERS) inhibitor (Ceapin 7, Cea or C) and conventional glucocorticoids (Dexamethasone, Dex or D), precisely modulating the ATF6/TGF-β/Smad3 signaling axis within macrophages. This approach calibrated the level of TGF-β stimulation on macrophages, promoting their polarization toward the M2c phenotype and suppressing excessive MMT polarization. The study indicates that the combination of ERS inhibitor and a first-line anti-inflammatory drug holds promise as an effective therapeutic approach for renal fibrosis resolution | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a TGF-β | |
| 650 | 4 | |a endoplasmic reticulum stress | |
| 650 | 4 | |a macrophage-to-myofibroblast transition cells | |
| 650 | 4 | |a renal fibrosis | |
| 650 | 4 | |a targeting | |
| 650 | 7 | |a Transforming Growth Factor beta |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 700 | 1 | |a Wang, Sijie |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Yilong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Litong |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xindong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Junlei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xuemeng |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Zhenyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Chunqi |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Miaomiao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yeqing |e verfasserin |4 aut | |
| 700 | 1 | |a You, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Fuchun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS nano |d 2007 |g 17(2023), 22 vom: 28. Nov., Seite 22508-22526 |w (DE-627)NLM18248100X |x 1936-086X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:22 |g day:28 |g month:11 |g pages:22508-22526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsnano.3c05998 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 22 |b 28 |c 11 |h 22508-22526 | ||